Biomarkers and prognostic stratification in psoriatic arthritis

Reumatismo

Volumn 64, Issue 2, 2012, Pages 88-98

  Bogliolo, L ^a   Crepaldi, G ^a   Caporali, R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biomarkers; Joint damage; Psoriatic arthritis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 4; C REACTIVE PROTEIN; COLLAGEN TYPE 2; COLONY STIMULATING FACTOR 1; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RHEUMATOID FACTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

BONE REMODELING; CHONDROLYSIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION; HEREDITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RADIOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; ULTRASOUND; VALIDITY;

EID: 84862488351     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2012.88     Document Type: Review

References (117)

1. Biomarkers Definition Working Group. Bi-omarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Quinn MA, Emery P. Are early arthritis clinics necessary? Best Pract Res Clin Rheumatol 2005; 19 (1): 1-17.
3. Breedveld F. The value of early intervention in RA: a window of opportunity. Clin Rheumatol 2011; 30 (Suppl 1): s33-s39.
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. 2010 Rheumaotid arthritis classification criteria. Arthritis Rheum 2010; 62: 2569-2581.
5. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 118-123.
6. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumps DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-643.
7. Smolen JS, Aletaha D, Bijlsma JW, Breed-veld FC, Boumpas D, Brumester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-637.
8. Schoels M, Bombardier C, Alethaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated pheripheral inflammatory arthritis: a systematic review. J Rheumatol 2011; 39: 20-25.
9. Kelling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, et al. Testing of the preliminary OMERACT validation criteria for biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol 2007; 34: 623-633.
10. Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011; 7: 282-289.
11. Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 2007; 1109: 287-295.
12. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 302-307.
13. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12: 203.
14. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-1095.
15. Vencovský J, Machácek S, Sedová L, Kafk-ová J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427-430.
16. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32: 231-238.
17. Johnson PM, Faulk WP. Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis. Clin Immunol Immun-opathol 1976; 6: 414-430.
18. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65: 453-458.
19. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007; 25 (5 Suppl 46): S22-S29.
20. Scirè CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power doppler signal predicts short-term relapse. Rheumatology (Oxford) 2009; 48: 1092-1097.
21. Wells AF, Haddad RH. Emerging role of ultrasonography in rheumatoid arthritis: optimizing diagnosis, measuring disease activity and identifying prognostic factors. Ultrasound Med Biol 2011; 37: 1173-1184.
22. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res 2011; 63: 675-688.
23. Cimmino MA, Barbieri F, Zampogna G, Ca-mellino D, Paparo F, Parodi M. Imaging in arthritis: quantifying effects of therapeutic intervention using MRI and molecular imaging. Swiss Med Wkly 2012; 141: w13326.
24. Boesen M, Ostergaard M, Cimmino MA, Kubassova O, Jensen KE, Bliddal H. MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. Eur J Radiol 2009; 71: 189-196.
25. Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000; 43: 2762-2770.
26. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemelä RK, Karjalainen A, et al. Bone oedema predicts erosive progression on wrist MRI in early RA - a 2 yr observational MRI and NC scintigraphy study. Rheumatology 2006; 45: 1542-1548.
27. Helliwell P, Marchesoni A, Peters M, Barker M, Wright VA. Re-evaluation of the osteoar-ticular manifestation of psoriasis. Br J Rheu-matol 1991; 30: 339-345.
28. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
29. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54: 2665-2673.
30. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, et al. The ClASsification for Psoriatic ARthritis (CASPAR) Criteria - A Retrospective Feasibility, Sensitivity, and Specificity Study. J Rheumatol. 2012; 39: 154-156.
31. Saber TP, Ng CT, Renard G, Lynch BM, Pon-tifex E, Walsh CAE, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
32. Chimienti MS, Graceffa D, Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 2011; 10: 636-640.
33. Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum 2008; 38: 83-100.
34. McInnes IB, O'Dell JR. State of the art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-1906.
35. Ritchlin CP, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease JP, et al. Biomarkers in Psoriais and Psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010; 37: 462-467.
36. Chandran V, Cook RJ, Edwin J, Shen H, Pellet FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology 2010; 49: 1399-1405.
37. Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, Ramonda R, et al. Laboratory findings in psoriatic arthritis. Reumatismo 2007; 59 (Suppl 1): 52-55.
38. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthrits: multivariate risk model. J Rheumatol 1995; 22: 675-679.
39. Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-399.
40. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-ra and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000; 19: 101-105.
41. Spadaro A, Taccari E, Riccieri V, Sensi F, Silli Scavelli A, Zoppini A. Interleukin 6 and soluble interleukin-receptor in psoriatic arthritis: correlation with clinical and laboratory parameters. Clin Exp Rheumatol 1996; 4: 413-416.
42. Alenius G M, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble inter-leukin-2 recptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol 2009; 27: 120-123.
43. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients. Arthritis Rheum 2008; 58: 2257-2267.
44. Arnett FC, Edworthy SM, Bloch DA, Mc-shane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
45. Bas S, Pernereg TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic test for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, antikeratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 809-814.
46. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-964.
47. Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatic (PMR) and rheumatoid arthritis with PMR like onset: a prospective study. Ann Rheum Dis 2001; 60: 1021-1024.
48. Johnson SR, schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 770-772.
49. Inanc N, Dalkihc E, Kamah S, Kasapoglu-Gunal E, Elbir Y, Direskeneli H, Inanc M. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007; 26: 17-23.
50. Morgan C, Lunt M, Bunn D, Scott DGI, Symmons DPM. Five-year outcome of primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology 2007; 46: 1819-1823.
51. Bogliolo L, Alpini C, Caporali R, Sciré CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis J Rheumatol 2005; 32: 511-515.
52. Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic toll for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1731-1736.
53. Schellekens GA, Visser H, de Jong BA, van der Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-163.
54. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365.
55. El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a scoring system for assessment of outcome of early un-differentiated inflammatory synovitis. Joint Bone Spine 2008; 75: 155-162.
56. Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes REM, et al. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 2008; 67: 1194-1195.
57. Boire G, Cosette P, Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005; 7: R592-R603.
58. Farragher TM, Goodson NJ, Naseem H, Sil-man AJ, Thomson W, Symmons D, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-369.
59. Van der Helm-van Mil A, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ. A prediction rule for disease outcome in patients with recent-onset undif-ferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 433-440.
60. Ursum J, Nielen MMJ, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BAC, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Ar thritis Res Ther 2008; 10: R12.
61. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008; 67: 801-807.
62. Kakumanu P, Sobel ES, Narain S, Li Y, Aka-ogi J, Yamasaki Y, Segal MS, et al. Citrul-line dependence of anti-cyclici citrullinated peptide antibodies in systemic lupus ery-thematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009; 36: 2682-2690.
63. Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 2009; 18: 713-717.
64. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, et al. Anti-cyclic citrullinated antibodies in pri mary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008; 10: R51.
65. Ingegnoli F, Galbiati V, Zeni S, Meani L, Zahalkova L, Lubatti C, et al. Use of antibodies recognizing cyclici citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 2007; 26: 510-514.
66. Cavagna L, Fusetti C, Montecucco CM, Ca-porali R. Anticyclic citrullinated antibodie as marker of erosive arthritis in antisyntetase syndrome. J Rheumatol 2010; 37: 9.
67. Helliwell PS, Porter G, Taylor WJ, CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis 2007; 66: 113-117.
68. Van der Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1145-1149.
69. Alenius GM, Berglin E, Rantapää Dahlgvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006; 65: 398-400.
70. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and anky-losing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011; 13 (Suppl 1): S4.
71. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogene-sis and bone erosion Arthritis Res Ther 2010; 12: R164.
72. Skoumal M, Haberhauer G, Fink A, Steiner A, Klingler A, Varga F, et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol 2008; 26: 1087-1090.
73. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl 2): ii14-ii17.
74. Sadek HA, Abdel-Nasser AM, El-Amawy TA, Hassan SZ. Rheumatic manifestations of psoriasis. Clin Rheumatol 2007; 26: 488-498.
75. Williamson L, Dockerty JL, Dalbeth N, Mc-Nally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictor of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004; 43: 85-88.
76. Ros Exposito S, Rodriguez Moreno J, Gomez Vaquero C, Campoy Reolid E, Roig Escofet D. Prognostic factors in the evolution of psoriatic arthritis. Med Clin (Barc) 1997; 108: 133-135.
77. Gladman DD. Inflammatory spinal disease in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 418-420.
78. Gladman DD, Brubacher B, Buskilia D, Langevitz P, Farewell VT. Differences in the expression of spondyloathropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin Invest Med 1993; 16: 1-7.
79. Gladman DD, Shuckett R, Russel ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med 1987; 62: 127-141.
80. Gladmann DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-812.
81. Bond SJ, Farewell VT, Schentag CT, Glad-man DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007; 66: 370-376.
82. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68-70.
83. Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreudschuh M, Assmann G. Swollen joint count in psoriatic arthritis is associated with progressiive radiological damage in hands and feet. Clin Exp Rheumatol. 2012; 30: 45-50.
84. Brown AK, Quinn Ma, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-3773.
85. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone oedema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1814-1827.
86. Guillemin F, Gerard N, van Leeuwen M, Smedtad LM, Kvient K, van den Heuvel W, et al. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003; 30: 2585-2589.
87. Gladman DD, Farewell VT, Wong KK, Hus-ted J. Mortality studies in psoriatic arthritis: results from a single outpatient centre II. Prognostic indicators for mortality. Arthritis Rheum 1998; 41: 1103-1110.
88. Weiner SM, Jurenz S, Uhl M, Lange-Nolde A, Warnatz K, Peter HH, et al. Ultrasonography in the assessment of peripheral joint involvement in psoriatic arthritis: a comparison with radiography, MRI and scintigraphy. Clin Rheumatol 2008; 27: 983-989.
89. Wiell C, Szkudlarek M, Hasselquist M, Møller JM, Vestergaard A, Nørregaard J, et al. Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis. Arthritis Res Ther 2007; 9: R119.
90. D'Auria MC, Scarpa R, Parodi M, Silvestri E, Garlaschi G, Cimmino MA. Magnetic resonance imaging of the peripheral joints in psoriatic arthritis. Reumatismo 2007; 59: 6-14.
91. McQueen FM, Dalbeth N, Doyle A. MRI in psoriatic arthritis: insights into pathogenesis and treatment response. Curr Rheumatol Rep 2008; 10: 303-310.
92. Cimmino MA, Parodi M, Zampogna G, Pa-paro F, Silvestri E, Garlaschi G, et al. Magnetic resonance imaging of the hand in psoriatic arthritis. J Rheumatol Suppl 2009; 83: 39-41.
93. Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol 2006; 126: 1205-1206.
94. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827-851.
95. Pedersen OB, Svendsen AJ, Ejstruo I, Skytthe A, Junker P. On the heritability of psoriatic arthritis. Disease concordance among monoxygotic and dizygotic twins. Ann Rheum Dis 2008; 67: 1417-1421.
96. Chandran V, Schentang CT, Brokbenk JE. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009; 68: 664-667.
97. Nograles KE, Brasington RD, Bowcock AM. New insights into pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheuma-tol 2009; 5: 83-91.
98. Queiro R, Alperin M, Lopez A, Sarasqueta C, Riestra JL, Ballina J. Clical expression, but not clinical outcome, may vary according to age at disease onset in psoriatic spondylitis. Joint Bone Spine 2008; 75: 544-547.
99. Queiro R, Gonzalez S, Lopez-Larrea C, Alperi M, Sarasqueta C, Riestra JL, et al. HLAC locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res Ther 2006; 8: R185.
100. Gladmann DD, Anhorn KAB, Scachter RK, Mervant U. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 586-592.
101. Korendowych E, Dixey J, Cox B, Jones S, McHugh N. The influence of the HLA-DR B1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol 2003; 30: 96-101.
102. Queiro-Silva R, Torre-Alonso JC, Tinturé-Eguren T, Lopez-Lagunas I. The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. Scand J Rheumatol 2004; 33: 318-322.
103. Grcevic D, Jajic Z, Kovacic N, Lukic IK, Velagic V, Grubisic F, et al. Peripheral blood expression profiles of bone morphgenetic proteins, tumor necrosis factor-super-family molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness J Rheumatol 2010; 37: 246-256.
104. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 2003; 111: 821-831.
105. Chiu YG, Shao T, Feng C, Mensah KA, Thullen, Schwarz EM, et al. CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis Arthritis Res Ther 2010; 12: R14.
106. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluid are characterized by CD8 and CD4 T cell clonal expansion appear antigen driven. J Immunol 2001; 166: 2878-2886.
107. Kruithof E, Baeten D, De Rycke L, Vandoor-en B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropa-thy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7: R569-R580.
108. Pontifex EK, Gerlag DM, Gogarty M, Vinke-noog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy. Arthritis Res Ther 2011; 13: R7.
109. Robinson H, Kelly S, Pitzalis C. Basic synovial biology and immunopathology in psoriatic arthritis. J Rheumatol 2009; 36 (Suppl 83).
110. van Kuijk AWR, Reinders-Blankert P, Smeets TJM, Dijkmans BAC, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 1551-1557.
111. Sciré CA, Epis O, Codullo V, Humby F, Morbini P, Manzo A, et al. Immunoistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of minimally invasive ultrasound guided synovial biopsy procedure. Arthritis Res Ther 2007; 9: R101.
112. Torre AJ, Rodriguez PA, Arribas CJ, Ballina GJ, Riestra NJ, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245-250.
113. McHugh NJ, Balakrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis. Reumatology (Oxford) 2003; 42: 778-783.
114. Sokoll KB, Helliwell PS. Comparision of disability and quality of life in rheumatoid arthritis and psoriatic arthritis. J Rheumatol 2001; 28: 1842-1846.
115. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis; an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
116. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006; 24 (Suppl 43): S83.
117. Gladman DD, Hing EN, Schentag CT, Cook RG. Remission in psoriatic arthritis. J Rheu-matol 2001; 28: 1045-1048.